Journal Articles

• Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. European Journal of Pharmaceutical Sciences. 2019; 140:105068. doi: 10.1016/j.ejps.2019.105068

• Olagunju A, Anweh D, Okafor O, Dickinson L, Richman D, Owen A, Adejuyigbe E. Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study [version 1; referees: awaiting peer review]. Wellcome Open Research. 2019; 4:34 (doi: 10.12688/wellcomeopenres.15072.1).

• Abdullahi ST, Olagunju A, Soyinka JO, Bolarinwa RA, Olarewaju OJ, Bakare-Odunola MT, Owen A, Khoo S. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: clinically significant drug-drug interaction? British Journal of Clinical Pharmacology. 2019; 85(3):540-550.

• Gini J, Olagunju A, Dickinson L, Waitt C, Neary M, Else LJ, Siccardi M, Khoo. Impact of Pharmacogenetics and Pregnancy on Tenofovir and Emtricitabine Pharmacokinetics. Pharmacogenomics. 2019; 20(4):217-223.

• Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, Mungofa S, Dawson R, Dorman S, Gupte N, Wiesner L, Jindani A, Harrison TS, Olagunju A, Egan D, Owen A, McIlleron HM. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents Chemotherapy. 2019; 27;63(4). pii: e01964-18. doi: 10.1128/AAC.01964-18.

• Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharmaceutical Nanotechnology. 2019; 7:3-23.